T1	PROC 44 55	TRATAMIENTO
#1	AnnotatorNotes T1	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T2	PROC 115 156	ESTUDIO PILOTO COMPARATIVO DE LA EFICACIA
T3	CHEM 160 170	EVOLOCUMAB
#2	AnnotatorNotes T3	C3529352; evolocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	CHEM 178 181	LDL
#3	AnnotatorNotes T4	C0023823; Low-Density Lipoproteins; Biologically Active Substance · Organic Chemical
T5	DISO 208 227	HIPERCOLESTEROLEMIA
#4	AnnotatorNotes T5	C0020443; Hypercholesterolemia; Disease or Syndrome
T6	DISO 250 278	HIPERCOLESTEROLEMIA FAMILIAR
#5	AnnotatorNotes T6	C0020445; Hypercholesterolemia, Familial; Disease or Syndrome
T7	PROC 304 315	TRATAMIENTO
#6	AnnotatorNotes T7	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T8	DISO 389 408	hipercolesterolemia
#7	AnnotatorNotes T8	C0020443; Hypercholesterolemia; Disease or Syndrome
T9	PROC 442 453	tratamiento
#8	AnnotatorNotes T9	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T10	CHEM 486 495	estatinas
#9	AnnotatorNotes T10	C0075191; statine; Amino Acid, Peptide, or Protein | C0360714; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Chemical · Pharmacologic Substance
T11	DISO 514 539	enfermedad cardiovascular
#10	AnnotatorNotes T11	C0007222; Cardiovascular Diseases; Disease or Syndrome
T12	CHEM 594 597	LDL
#11	AnnotatorNotes T12	C0023823; Low-Density Lipoproteins; Biologically Active Substance · Organic Chemical
T13	CHEM 682 692	evolocumab
#12	AnnotatorNotes T13	C3529352; evolocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T14	PROC 716 736	ingreso hospitalario
#13	AnnotatorNotes T14	C0184666; Hospital admission; Health Care Activity
T15	ANAT 826 840	cardiovascular
#14	AnnotatorNotes T15	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T16	PROC 926 950	consentimiento informado
#15	AnnotatorNotes T16	C0811741; Obtain informed written consent; Health Care Activity
T17	DISO 819 840	evento cardiovascular
T18	DISO 59 78	HIPERCOLESTEROLEMIA
#16	AnnotatorNotes T18	C0020443; Hypercholesterolemia; Disease or Syndrome
T19	CHEM 83 93	EVOLOCUMAB
#17	AnnotatorNotes T19	C3529352; evolocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T20	PROC 178 190	LDL-AFÉRESIS
T21	CHEM 320 330	EVOLOCUMAB
#18	AnnotatorNotes T21	C3529352; evolocumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T22	CHEM 413 416	LDL
#19	AnnotatorNotes T22	C0023823; Low-Density Lipoproteins; Biologically Active Substance · Organic Chemical
T23	PROC 413 427	LDL-colesterol
#20	AnnotatorNotes T23	C0202117; Low density lipoprotein cholesterol measurement; Laboratory Procedure
T24	ANAT 525 539	cardiovascular
#21	AnnotatorNotes T24	C0007226; Cardiovascular system; Body System | C3887460; Cardiovascular; Body Location or Region
T25	PROC 594 606	LDL-aféresis
T26	Date 12 16	2016
T27	LIVB 194 203	PACIENTES
#22	AnnotatorNotes T27	C0030705; Patients; Patient or Disabled Group
T28	LIVB 359 368	pacientes
#23	AnnotatorNotes T28	C0030705; Patients; Patient or Disabled Group
T29	Age 378 386	>18 años
T31	Dose 461 482	dosis máxima tolerada
#24	AnnotatorNotes T31	C0752079; Maximum Tolerated Dose; Quantitative Concept
T32	LIVB 549 558	pacientes
#25	AnnotatorNotes T32	C0030705; Patients; Patient or Disabled Group
T33	Frequency 607 621	quincenalmente
T34	Duration 759 781	los tres últimos meses
T35	Duration 844 858	los tres meses
T36	Neg_cue 896 912	Incapacidad para
A1	Assertion T16 Negated
A2	Status T11 History_of
A3	Assertion T13 Contraindicated
A4	Status T14 History_of
#26	AnnotatorNotes T2	C0031928; Pilot Projects; Research Activity + C1579762; comparative study research; Research Activity + C1707887; Efficacy Study; Research Activity 
#27	AnnotatorNotes T20	C2599009; LDL apheresis procedure; Therapeutic or Preventive Procedure 
#28	AnnotatorNotes T25	C2599009; LDL apheresis procedure; Therapeutic or Preventive Procedure 
#29	AnnotatorNotes T17	C1320716; Cardiovascular event; Finding
R1	Negation Arg1:T36 Arg2:T16	
R2	Used_for Arg1:T19 Arg2:T1	
R3	Experiences Arg1:T27 Arg2:T3	
R4	Experiences Arg1:T27 Arg2:T20	
R5	Experiences Arg1:T27 Arg2:T5	
R6	Used_for Arg1:T21 Arg2:T7	
R7	Has_Age Arg1:T28 Arg2:T29	
T30	Result_or_Value 428 438	>100 mg/dl
R8	Has_Result_or_Value Arg1:T23 Arg2:T30	
R9	Has_Dose_or_Strength Arg1:T10 Arg2:T31	
R10	Used_for Arg1:T10 Arg2:T9	
T37	Quantifier_or_Qualifier 540 546	severa
#30	AnnotatorNotes T37	C1547227; Severe - Severity of Illness Code; Intellectual Product
R11	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T37	
R12	Location_of Arg1:T24 Arg2:T11	
R13	Has_Frequency Arg1:T25 Arg2:T33	
R14	Experiences Arg1:T32 Arg2:T25	
R15	Overlap Arg1:T14 Arg2:T34	
R16	Location_of Arg1:T15 Arg2:T17	
R17	Overlap Arg1:T17 Arg2:T35	
T38	CONC 795 804	inclusión
#31	AnnotatorNotes T38	C1512693; Inclusion; Qualitative Concept
R18	Before Arg1:T14 Arg2:T38	
T39	CONC 872 881	inclusión
#32	AnnotatorNotes T39	C1512693; Inclusion; Qualitative Concept
R19	Before Arg1:T17 Arg2:T39	
R20	Before Arg1:T11 Arg2:T8	
A5	Experiencer T27 Patient
A6	Experiencer T28 Patient
A7	Experiencer T32 Patient
